As of May 31, 2025, Adamas Pharmaceuticals Inc (ADMS) reports a Forward P/E of N/A.
Forward P/E gauges the price investors pay for each dollar of anticipated earnings, offering insight into a stock's future valuation.
Comparing Adamas Pharmaceuticals Inc's Forward P/E to Peers
To better understand Adamas Pharmaceuticals Inc's position, it's useful to compare its Forward P/E against industry peers. Below are selected comparisons:
| Company | Forward P/E |
|---|---|
| Adamas Pharmaceuticals Inc (ADMS) | - |
| Theratechnologies Inc (TH.TO) | 77.87 |
| Covalon Technologies Ltd (COV.V) | 29.52 |
| ADMA Biologics Inc (ADMA) | 29.27 |
| Vertex Pharmaceuticals Inc (VRTX) | 24.37 |
| Regeneron Pharmaceuticals Inc (REGN) | 16.27 |
Compared to its competitors, Adamas Pharmaceuticals Inc's Forward P/E is difficult to compare due to insufficient data.